Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Non-Current Debt (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Non-Current Debt data on record, last reported at $71.3 million in Q4 2025.

  • For Q4 2025, Non-Current Debt rose 4.13% year-over-year to $71.3 million; the TTM value through Dec 2025 reached $71.3 million, up 4.13%, while the annual FY2025 figure was $71.3 million, 4.13% up from the prior year.
  • Non-Current Debt reached $71.3 million in Q4 2025 per OCUL's latest filing, up from $70.6 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $71.3 million in Q4 2025 and bottomed at $14.9 million in Q1 2021.
  • Average Non-Current Debt over 5 years is $46.0 million, with a median of $45.2 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: tumbled 35.15% in 2021, then soared 188.08% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $25.0 million in 2021, then grew by 1.03% to $25.3 million in 2022, then surged by 160.47% to $65.8 million in 2023, then grew by 4.13% to $68.5 million in 2024, then rose by 4.13% to $71.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $71.3 million in Q4 2025, $70.6 million in Q3 2025, and $69.9 million in Q2 2025.